Cytokinetics, Inc. (CYTK) EVP Fady Ibraham Malik Sells 1,500 Shares

Cytokinetics, Inc. (NASDAQ:CYTK) EVP Fady Ibraham Malik sold 1,500 shares of the stock in a transaction dated Thursday, November 1st. The shares were sold at an average price of $6.68, for a total value of $10,020.00. Following the completion of the sale, the executive vice president now owns 88,567 shares of the company’s stock, valued at approximately $591,627.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Fady Ibraham Malik also recently made the following trade(s):

  • On Thursday, October 4th, Fady Ibraham Malik sold 1,500 shares of Cytokinetics stock. The shares were sold at an average price of $9.14, for a total value of $13,710.00.
  • On Thursday, September 6th, Fady Ibraham Malik sold 1,500 shares of Cytokinetics stock. The shares were sold at an average price of $8.00, for a total value of $12,000.00.

CYTK traded up $0.47 on Friday, reaching $7.40. The company’s stock had a trading volume of 717,000 shares, compared to its average volume of 332,296. The company has a market capitalization of $360.55 million, a P/E ratio of -2.86 and a beta of 1.42. Cytokinetics, Inc. has a 1 year low of $6.20 and a 1 year high of $13.65. The company has a debt-to-equity ratio of 0.41, a quick ratio of 8.95 and a current ratio of 8.95.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.11. The business had revenue of $10.64 million during the quarter, compared to analysts’ expectations of $2.23 million. As a group, equities research analysts forecast that Cytokinetics, Inc. will post -2.06 earnings per share for the current fiscal year.

A number of equities research analysts have recently issued reports on the company. BidaskClub lowered Cytokinetics from a “buy” rating to a “hold” rating in a research note on Thursday, July 19th. Cantor Fitzgerald set a $14.00 target price on Cytokinetics and gave the company a “buy” rating in a research note on Friday. HC Wainwright set a $21.00 target price on Cytokinetics and gave the company a “buy” rating in a research note on Friday. ValuEngine upgraded Cytokinetics from a “sell” rating to a “hold” rating in a research note on Thursday, August 23rd. Finally, Zacks Investment Research downgraded Cytokinetics from a “hold” rating to a “sell” rating in a report on Wednesday, October 3rd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. Cytokinetics currently has an average rating of “Buy” and an average target price of $13.00.

A number of institutional investors and hedge funds have recently modified their holdings of CYTK. DRW Securities LLC boosted its holdings in Cytokinetics by 91.4% in the second quarter. DRW Securities LLC now owns 26,797 shares of the biopharmaceutical company’s stock valued at $222,000 after purchasing an additional 12,797 shares during the last quarter. Fox Run Management L.L.C. boosted its holdings in Cytokinetics by 181.8% in the second quarter. Fox Run Management L.L.C. now owns 31,627 shares of the biopharmaceutical company’s stock valued at $263,000 after purchasing an additional 20,405 shares during the last quarter. A.R.T. Advisors LLC purchased a new position in Cytokinetics in the first quarter valued at about $350,000. UBS Group AG boosted its holdings in Cytokinetics by 226.7% in the first quarter. UBS Group AG now owns 54,910 shares of the biopharmaceutical company’s stock valued at $396,000 after purchasing an additional 38,105 shares during the last quarter. Finally, DAFNA Capital Management LLC purchased a new position in Cytokinetics in the second quarter valued at about $576,000. 68.39% of the stock is owned by hedge funds and other institutional investors.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.

See Also: Stock Symbols and CUSIP Explained

Insider Buying and Selling by Quarter for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply